ASX Share rice
Fri 14 Aug 2020 - 12:44:pm (Sydney)

BNO Share Price

BIONOMICS LIMITEDBNOPharmaceuticals, Biotechnology & Life Sciences

BNO Company Information


Bionomics Limited





GIC Industry:


GIC Sub Industry:



31 Dalgleish Street Thebarton Australia 5031


61 8 8354 6100

Exec. Chairman:

Dr. Errol B. De Souza

Acting Chief Financial Officer:

Mr. Adrian Hinton

Legal Counsel & Company Sec.:

Mr. Jack Moschakis B.E., BEc, DipLaw(BAB), GDipBA, FCIS

Consultant Chief Medical Officer of Clinical Neuroscience:

Prof. Paul Rolan

Company Overview:

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's lead product candidate includes BNC210, a negative allosteric modulator, which is in various clinical trials for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. In addition, the company offers contract research services. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

BNO Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


BNO CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


BNO Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Interest Expense:


Income Tax Expense:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


BNO Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:


Good Will:


Other Assets:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities (Other):


Non Current Liabilities Total:


BNO Share Price History

BNO News

02 Jun, 2020
Bionomics A$20-A$22 million recapitalisation led by Apeiron Investment Group
31 Mar, 2020
Published preclinical findings for Bionomics Limited's BNC375 explore the potential of this novel molecule to improve cognitive impairment.
20 Mar, 2020
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...
11 Dec, 2019
Bionomics Limited has accepted offer from Domain Therapeutics for subsidiaries Neurofit SAS and PC SAS (Prestwick Chemical) in France.
04 Nov, 2019
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders.
23 Sep, 2019
If you own shares in Bionomics Limited (ASX:BNO) then it's worth thinking about how it contributes to the volatility...